Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.38 |
| ▸ | HTR2C | P28335 | 7/20 | 0.38 |
| ▸ | HRH1 | P35367 | 6/20 | 0.38 |
| ▸ | DRD2 | P14416 | 6/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.38 |
| ▸ | DRD1 | P21728 | 5/20 | 0.38 |
| ▸ | DRD3 | P35462 | 5/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037140 | 0.94 | MAPK1 (0.36) | HTR2AHTR2CHRH1DRD2ADRA2A | |
| SCHEMBL4042515 | 0.90 | ALDH1A1 (0.37) | HTR2AHTR2CHRH1ADRA2ADRD3 | |
| Hydrochloric Acid SCHEMBL4039575 | 0.89 | KDM4E (0.36) | HTR2AHTR2CHRH1ADRA2ADRD3 | |
| SCHEMBL4037508 | 0.87 | HTR2C (0.35) | HTR2AHTR2CHRH1DRD2ADRA2A | |
| Hydrochloric Acid SCHEMBL4040618 | 0.86 | HTR2C (0.35) | HTR2AHTR2CHRH1DRD2ADRA2A | |
| SCHEMBL5428745 | 0.86 | HDAC3 (0.33) | ESR1MAPK1MAOAACHEADRB1 | |
| SCHEMBL6335810 | 0.85 | MAPK1 (0.38) | HTR2AHTR2CHRH1DRD2ADRA2A | |
| SCHEMBL4040257 | 0.84 | AHR (0.33) | ESR1MAOAACHEHRH3ADRB1 | |
| SCHEMBL6341181 | 0.83 | MAPK1 (0.36) | HTR2AHTR2CHRH1DRD2ADRA2A | |
| SCHEMBL6336542 | 0.83 | MAPK1 (0.36) | HTR2AHTR2CHRH1DRD2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284977-B1 | THIENODIBENZOAZULENE COMPOUNDS AS TUMOR NECROSIS FACTOR INHIBITORS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-06-24 | — | — | EP | claimed |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA D.D. (HR) | 2005-08-04 | — | — | US | claimed |
| US-6897211-B2 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-05-24 | — | — | US | claimed |
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO | 2003-08-14 | — | — | US | claimed |
| EP-2059508-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008020124-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-02-21 | — | — | WO | disclosed |
| US-6897211-B2 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-05-24 | — | — | US | disclosed |
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | TNF, IL1B, IL1A | HTR2A 3512/4885HTR2C 3559/4885HRH1 413/4885 |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | TNF, IL1B, IL1A | HTR2A 3534/4885HTR2C 3616/4885HRH1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.